Listed

Edwards Lifesciences Corp: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Oct 25, 2019 and accepted by EDGAR at Oct 25, 2019, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$1.09bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2019-01-01 to 2019-09-30$3.17bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-07-01 to 2019-09-30$292.4mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2019-01-01 to 2019-09-30$828.2mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-07-01 to 2019-09-30$801.6mus-gaap:GrossProfit
Gross profit9 months2019-01-01 to 2019-09-30$2.35bnus-gaap:GrossProfit
Research and development3 months2019-07-01 to 2019-09-30$195.5mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$558.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-07-01 to 2019-09-30$306.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2019-01-01 to 2019-09-30$895.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-07-01 to 2019-09-30$294.3mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30$836.0mus-gaap:OperatingIncomeLoss
Income tax3 months2019-07-01 to 2019-09-30$27.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30$84.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30$274.7mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2019-01-01 to 2019-09-30$766.7mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2019-07-01 to 2019-09-30$1.30us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30$3.61us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-07-01 to 2019-09-30$1.32us-gaap:EarningsPerShareBasic
Basic EPS9 months2019-01-01 to 2019-09-30$3.68us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-07-01 to 2019-09-30212,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2019-01-01 to 2019-09-30212,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2019-01-01 to 2019-09-30$780.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$182.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2019-01-01 to 2019-09-30$263.3mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-09-30$1.19bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$2.74bnus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$5.97bnus-gaap:Assets
Current liabilitiesAt period end2019-09-30$775.8mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2019-09-30$594.2mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2019-09-30$3.81bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-19-000024. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.